lipases Inhibitors
5 drugsAbout lipases
Lipases are a class of enzymes catalyzing the hydrolysis of fats (lipids), breaking down triglycerides into fatty acids and glycerol, which is crucial for digestion and nutrient absorption.
Lipases are clinically relevant targets with five FDA-approved therapies, though no genetic evidence currently links them to specific diseases, highlighting an opportunity for further research.
The lipase drug landscape includes five approved biologics, such as CREON, ZENPEP, VIOKACE, PERTZYE, and PANCREAZE, marketed by companies like AbbVie and EURAND PHARMA LTD for various indications.
Top lipases Drugs
The competitive landscape includes five companies with approved drugs, including AbbVie and EURAND PHARMA LTD.
Low market concentration suggests relatively low barriers to entry, but also potential for intense competition.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| PERTZYE | DIGESTIVE CARE INC | 2012 | 1 |
| CREON | AbbVie | 2009 | 1 |
lipases Drug Modality Landscape
Modalities
Routes of Administration
lipases requires biologic approaches (enzyme), likely due to its structure or location.
The lack of small molecule or antibody drugs indicates a whitespace opportunity for novel lipase inhibitors or modulators.
lipases Clinical Trials 23 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on lipases. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 0 | 3 | 1 | 0% |
| Phase 2 | 6 | 1 | 2 | 3 | 33% |
| Phase 3 | 2 | 1 | 1 | 0 | 50% |
| Phase 4 | 11 | 4 | 6 | 1 | 40% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
lipases Drug Approval Timeline (2009 - 2012)
The approval timeline spans from 2009 (CREON) to 2012 (PERTZYE), indicating a relatively short approval window.
The limited approval window suggests market saturation or challenges in developing new lipase-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 5 companies competing
- • Market share by company
Full Drug Portfolio
- • All 5 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 5-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 17 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on lipases. A trial counts if an approved drug acting on lipases is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.